HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape | Zendy

Virginia Carroll | Zendy; Alfredo GarzinoDemo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape

Author(s) -

Virginia Carroll,

Alfredo GarzinoDemo

Publication year - 2015

Publication title -

pathogens and disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.983

H-Index - 105

ISSN - 2049-632X

DOI - 10.1093/femspd/ftv044

Subject(s) - cart , lymphoma , medicine , immunology , follicular lymphoma , antiretroviral therapy , epidemiology , human immunodeficiency virus (hiv) , viral load , mechanical engineering , engineering

HIV infection increases the risk of many types of cancer, including lymphoma. Combination antiretroviral therapy (cART) has reduced, but not eliminated, the risk of HIV-associated lymphoma. There has been a substantial shift in the subtypes of lymphoma observed in HIV-infected patients treated with cART. In this review, we will first outline these changes based on epidemiological studies and describe the impact of cART on lymphoma risk and mortality. Then, we will discuss some immunological factors that may contribute to the increased risk of lymphoma persisting after the administration of cART, including immunological non-response to therapy, chronic B-cell activation and dysfunction, T follicular helper cells, natural killer cells and altered lymphopoiesis. A better understanding of the pathophysiologic mechanisms of HIV-associated lymphoma under effective cART will inform future treatment strategies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research